BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Alphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...

March 16, 2026 | News

Vaxcellbio And Reber Genetics Form Strategic Partnership To Expand Companion Animal Immunotherapy Across Asia

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced on Wednesday that it has signed a Master Partnership Agreement (MPA) wi...

March 12, 2026 | News

Leads Biolabs Doses First Patient In Phase II Trial Of PD L1 4 1BB Bispecific Antibody For Esophageal Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has bee...

March 10, 2026 | News

Servier To Acquire Day One Biopharmaceuticals For $2.5 Billion To Strengthen Rare Oncology Pipeline

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with...

March 09, 2026 | News

Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...

March 02, 2026 | News

Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic

Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...

March 02, 2026 | News

WuXi XDC And Earendil Labs Forge Strategic Alliance To Advance Next Generation AI Designed ADCs

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializin...

March 02, 2026 | News

Japan Approves Alpha DaRT To Expand Treatment Options In Head And Neck Cancer

Offering a New Option for Head and Neck Cancer Treatment HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor tr...

February 27, 2026 | News

Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...

February 25, 2026 | News

Etherna And Almirall Advance LAD116 mRNA LNP Therapy Into IND Enabling Studies For Non Melanoma Skin Cancer

etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one o...

February 25, 2026 | News

CStone Secures UK MHRA Approval For Sugemalimab In Stage III Non Small Cell Lung Cancer

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products...

February 24, 2026 | News

AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer

– Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...

February 24, 2026 | News

ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced a partnership with Accord Healthcare to provide access to ANKTI...

February 23, 2026 | News

ANKTIVA Plus BCG Secures European Commission Authorization As First Immunotherapy For BCG Unresponsive NMIBC

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...

February 20, 2026 | News

Stay Connected